tiprankstipranks
Trending News
More News >
Nova Eye Medical (AU:EYE)
ASX:EYE
Advertisement

Nova Eye Medical (EYE) AI Stock Analysis

Compare
18 Followers

Top Page

AU:EYE

Nova Eye Medical

(Sydney:EYE)

Rating:56Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Nova Eye Medical's stock score is primarily impacted by its strong revenue growth, which is offset by significant profitability and cash flow challenges. Technical indicators show positive market momentum, but valuation metrics point to fundamental weaknesses, leading to a moderate overall score.

Nova Eye Medical (EYE) vs. iShares MSCI Australia ETF (EWA)

Nova Eye Medical Business Overview & Revenue Model

Company DescriptionNova Eye Medical (EYE) is a medical technology company specializing in the development and commercialization of innovative ophthalmic treatment solutions. The company focuses primarily on addressing glaucoma and other eye-related disorders through minimally invasive surgical devices and technologies. Nova Eye Medical operates within the healthcare and medical devices sector, providing cutting-edge solutions designed to improve patient outcomes and enhance the quality of life for individuals with eye health issues.
How the Company Makes MoneyNova Eye Medical generates revenue primarily through the sale of its proprietary ophthalmic products and technologies. The company's key revenue streams include the commercialization of its glaucoma treatment devices, such as the iTrack and Molteno3, which are utilized by eye care professionals globally. Additionally, Nova Eye Medical may engage in strategic partnerships and collaborations with healthcare providers and institutions to expand its market reach and drive sales. The company's earnings are also influenced by its research and development efforts, which lead to the introduction of new and improved treatment solutions in the ophthalmic field.

Nova Eye Medical Financial Statement Overview

Summary
Nova Eye Medical shows strong revenue growth but struggles with profitability and cash flow management, posing challenges for long-term sustainability.
Income Statement
55
Neutral
Nova Eye Medical has shown a strong revenue growth of 37.06% from 2023 to 2024, indicating a positive growth trajectory. However, the company continues to struggle with profitability, evidenced by negative EBIT and Net Income margins, which suggests ongoing challenges in cost management and operational efficiency.
Balance Sheet
60
Neutral
The balance sheet of Nova Eye Medical is relatively stable with a moderate debt-to-equity ratio of 0.16 in 2024, indicating low leverage. However, the declining equity ratio from 2023 to 2024 suggests potential risks in maintaining asset efficiency and shareholder value over time.
Cash Flow
50
Neutral
Nova Eye Medical's cash flow statements reveal negative free cash flow, reflecting challenges in generating cash from operations. The operating cash flow to net income ratio is negative, indicating cash flow issues. Despite these challenges, financing activities have provided some liquidity support.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue23.32M17.02M13.38M13.39M12.77M
Gross Profit20.19M842.00K-765.00K1.77M-1.64M
EBITDA-5.98M-9.48M-7.89M-3.67M-5.75M
Net Income-8.79M-15.29M-7.50M-4.36M-6.99M
Balance Sheet
Total Assets29.88M30.36M36.63M41.99M116.74M
Cash, Cash Equivalents and Short-Term Investments6.15M7.42M8.00M17.80M95.65M
Total Debt3.35M1.53M1.94M3.70M3.34M
Total Liabilities8.55M7.17M6.23M6.66M16.16M
Stockholders Equity21.33M23.19M30.40M35.34M100.59M
Cash Flow
Free Cash Flow-8.31M-7.52M-10.27M-15.13M3.79M
Operating Cash Flow-7.86M-6.72M-4.68M-12.90M5.45M
Investing Cash Flow-325.00K-800.00K-4.58M-3.22M88.26M
Financing Cash Flow6.91M6.82M-402.00K-61.61M-13.29M

Nova Eye Medical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.14
Price Trends
50DMA
0.12
Positive
100DMA
0.11
Positive
200DMA
0.14
Positive
Market Momentum
MACD
<0.01
Negative
RSI
62.91
Neutral
STOCH
69.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EYE, the sentiment is Positive. The current price of 0.14 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.12, and above the 200-day MA of 0.14, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 62.91 is Neutral, neither overbought nor oversold. The STOCH value of 69.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EYE.

Nova Eye Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$41.20M-50.50%39.08%53.31%
54
Neutral
AU$56.70M-8.08%-5.62%-225.71%
52
Neutral
$7.59B0.18-63.14%2.16%16.34%0.64%
51
Neutral
AU$153.50M-58.61%-74.88%
48
Neutral
AU$11.78M-98.08%-7.44%30.34%
47
Neutral
AU$43.37M-135.33%-27.58%33.69%
41
Neutral
AU$119.47M-35.20%4.68%-155.42%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:EYE
Nova Eye Medical
0.15
-0.10
-40.82%
AU:CMP
Compumedics Limited
0.32
0.02
6.67%
AU:CYC
Cyclopharm Limited
1.02
-0.53
-34.19%
AU:MX1
Micro-X Ltd.
0.06
-0.01
-14.29%
AU:EMV
EMvision Medical Devices Ltd.
1.80
-0.19
-9.55%
AU:CBL
Control Bionics Ltd.
0.04
-0.01
-20.00%

Nova Eye Medical Corporate Events

Nova Eye Medical Reports Record Revenue and Corrects Cash Flow Statement
Jul 29, 2025

Nova Eye Medical Limited announced a correction in their Quarterly Activities and Appendix 4C Cash Flow Report for June 2025, adjusting the cash and cash equivalents figure to A$5,054,000. The company reported a record full-year revenue of A$29.2 million for FY25, a 23% increase from the previous year, with significant sales growth in the second half. The glaucoma segment achieved a positive EBITDA in the second half of FY25, and the company forecasts sales revenue between US$21 million to US$24 million for FY26, excluding China, aiming for breakeven EBITDA in the first half of FY26.

Nova Eye Medical Achieves Record Revenue and Improved Profitability in FY25
Jul 29, 2025

Nova Eye Medical Limited reported a record full-year revenue of A$29.2 million for the fiscal year 2025, marking a 23% increase from the previous year. The company’s glaucoma segment showed significant improvement with a positive EBITDA in the second half of FY25. The company also reduced its cash outflow from operations and aims for breakeven EBITDA in the first half of FY26, indicating a positive trajectory in financial performance and operational efficiency.

Nova Eye Medical Announces Investor Webinar for Quarterly Report Review
Jul 28, 2025

Nova Eye Medical Limited has announced an upcoming Investor Webinar scheduled for July 31, 2025, where Managing Director Tom Spurling will review the company’s June Quarterly Report. This event provides an opportunity for shareholders and interested parties to engage with the company, potentially impacting investor relations and market perception.

Nova Eye Medical Announces Quotation of New Securities
Jul 22, 2025

Nova Eye Medical Limited has announced the quotation of 7,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) as part of an employee incentive scheme. This move is expected to enhance employee engagement and align their interests with company performance, potentially impacting the company’s operational dynamics and market positioning positively.

Nova Eye Medical Hosts Investor Webinar to Discuss Ophthalmic Innovations
Jul 8, 2025

Nova Eye Medical Limited has announced an investor webinar, highlighting their commitment to transparency and engagement with stakeholders. The company is addressing the challenges associated with high intraocular pressure (IOP), which can lead to optic nerve damage and blindness, by focusing on solutions that prevent fluid buildup in the eye.

Nova Eye Medical Achieves Record Revenues in FY25
Jul 8, 2025

Nova Eye Medical Limited has reported record revenues of A$28.8 million for the fiscal year ending June 30, 2025, marking a 21% increase from the previous year. This growth is attributed to the strong performance of their iTrack™ Advance device, particularly in the US market, where sales increased by 25%. The company anticipates continued revenue growth in FY26, reflecting the growing global recognition of its technology and successful market penetration.

Nova Eye Medical to Host Investor Webinar on FY25 Sales Results
Jul 4, 2025

Nova Eye Medical Limited has announced an upcoming Investor Webinar scheduled for July 9, 2025, where Managing Director Tom Spurling will discuss the company’s sales results for the fiscal year 2025. This event provides an opportunity for stakeholders to engage with the company, potentially impacting investor relations and market perception of Nova Eye Medical’s performance and strategic direction.

Nova Eye Medical Announces Cessation of Performance Rights
Jun 20, 2025

Nova Eye Medical Limited has announced the cessation of 7,000 performance rights, as the conditions for these securities have not been met or have become incapable of being satisfied. This development may impact the company’s capital structure and could have implications for its stakeholders, reflecting a potential shift in the company’s operational or strategic focus.

Nova Eye Medical Expands Market Presence with New Securities Quotation
May 9, 2025

Nova Eye Medical Limited has announced the application for quotation of 21,000 ordinary fully paid securities on the Australian Securities Exchange, issued under an employee incentive scheme. This move reflects the company’s ongoing efforts to enhance its market presence and incentivize its workforce, potentially impacting its operational dynamics and stakeholder engagement.

Nova Eye Medical Announces Investor Webinar Amid Market Growth
May 6, 2025

Nova Eye Medical Limited has announced an investor webinar, highlighting its commitment to delivering on promises by selling highly effective ophthalmic products that are in demand among eye surgeons. This announcement underscores the company’s strategic focus on capitalizing on a growing market, which could enhance its industry positioning and potentially benefit stakeholders.

Nova Eye Medical Issues Shares to Consultant, Bolstering Market Position
May 5, 2025

Nova Eye Medical Ltd has issued 45,236 shares to an American consultant as part of a consulting agreement. This move, executed without the need for disclosure under the Corporations Act, signifies the company’s compliance with regulatory requirements and may enhance its operational capabilities and market positioning.

Nova Eye Medical to Quote New Securities on ASX
May 5, 2025

Nova Eye Medical Limited has announced the quotation of 45,236 ordinary fully paid securities on the ASX, effective May 6, 2025. This move is part of a consulting agreement in America aimed at enhancing clinical marketing, new product development, peer-to-peer education, and clinical investigations, which could strengthen the company’s market position and stakeholder engagement.

Nova Eye Medical Announces Investor Webinar to Discuss Record Sales and Future Growth Opportunities
Apr 30, 2025

Nova Eye Medical has announced an upcoming Investor Webinar on 6 May 2025, where Managing Director Tom Spurling will discuss the company’s March 2025 Quarterly Activities and Cashflow Report. The report highlights record US sales, revenue growth, and improved profitability in glaucoma treatments. Additionally, Nova Eye Medical is exploring opportunities to expand its iTrack™ technology into ocular drug delivery markets, indicating potential future growth and innovation in their product offerings.

Nova Eye Medical Reports Record Sales and Identifies New Growth Opportunities
Apr 29, 2025

Nova Eye Medical Limited reported strong financial performance for the March 2025 quarter, with a 27% increase in sales compared to the previous corresponding period, excluding China. The company achieved record sales in the USA, contributing to a significant reduction in losses within the glaucoma segment. The company also identified potential growth opportunities in ocular drug delivery using its proprietary iTrack™ technology, further strengthening its market position.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 22, 2025